CN103200950B - 新颖的耳他汀衍生物及其用途 - Google Patents

新颖的耳他汀衍生物及其用途 Download PDF

Info

Publication number
CN103200950B
CN103200950B CN201180037305.4A CN201180037305A CN103200950B CN 103200950 B CN103200950 B CN 103200950B CN 201180037305 A CN201180037305 A CN 201180037305A CN 103200950 B CN103200950 B CN 103200950B
Authority
CN
China
Prior art keywords
formula
methyl
compound
methoxy
represent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180037305.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103200950A (zh
Inventor
H-G·莱尔臣
B·斯泰尔特-路德维希
S·戈尔费亚
J·舒马赫
U·科兰兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of CN103200950A publication Critical patent/CN103200950A/zh
Application granted granted Critical
Publication of CN103200950B publication Critical patent/CN103200950B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201180037305.4A 2010-06-10 2011-06-06 新颖的耳他汀衍生物及其用途 Active CN103200950B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10165550.4 2010-06-10
EP10165550 2010-06-10
EP11158464 2011-03-16
EP11158464.5 2011-03-16
PCT/EP2011/059300 WO2011154359A1 (de) 2010-06-10 2011-06-06 Neue auristatin-derivate und ihre verwendung

Publications (2)

Publication Number Publication Date
CN103200950A CN103200950A (zh) 2013-07-10
CN103200950B true CN103200950B (zh) 2016-03-16

Family

ID=44275637

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180037305.4A Active CN103200950B (zh) 2010-06-10 2011-06-06 新颖的耳他汀衍生物及其用途

Country Status (7)

Country Link
US (1) US8722629B2 (enExample)
EP (1) EP2579887B1 (enExample)
JP (1) JP5791707B2 (enExample)
CN (1) CN103200950B (enExample)
CA (1) CA2801971C (enExample)
ES (1) ES2528956T3 (enExample)
WO (1) WO2011154359A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553874T3 (es) 2010-09-29 2015-12-14 Seattle Genetics, Inc. N-Carboxialquil-auristatinas y su uso
CA2829736C (en) 2011-03-16 2020-07-21 Seattle Genetics, Inc. N-carboxyalkylauristatins and use thereof
EP3501546A3 (de) * 2011-04-21 2019-09-18 Seattle Genetics, Inc. Cystein-wirkstoff konjugate und ihre verwendung
TWI589592B (zh) 2011-11-17 2017-07-01 輝瑞股份有限公司 胞毒性肽類以及其抗體藥物共軛體
MX2014007121A (es) * 2011-12-14 2014-09-04 Seattle Genetics Inc Nuevos conjugados de principio activo-ligante (adc) y su uso.
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
US9522876B2 (en) 2013-03-15 2016-12-20 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
SG11201605260VA (en) 2013-12-27 2016-07-28 Zymeworks Inc Var2csa-drug conjugates
EP3134124B1 (en) 2014-04-25 2019-02-20 Pierre Fabre Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
CN106470708B (zh) 2014-04-25 2019-12-31 皮埃尔法布雷医药公司 抗体-药物-缀合物和其用于治疗癌症的用途
EP3194421B1 (en) 2014-09-17 2021-11-03 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
CN106279352B (zh) 2015-05-29 2020-05-22 上海新理念生物医药科技有限公司 海兔毒素10的衍生物及其应用
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
CN108690119B (zh) * 2018-06-04 2022-04-19 莎穆(上海)生物科技有限公司 一种伊文思蓝修饰的多肽类前药及其制备和应用
EP4319820A1 (en) 2021-04-10 2024-02-14 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
JP7742892B2 (ja) 2021-04-23 2025-09-22 ジェンマブ エー／エス 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
EP4400121A1 (en) 2021-09-03 2024-07-17 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
TW202547866A (zh) 2024-01-10 2025-12-16 丹麥商珍美寶股份有限公司 Ｓｌｉｔｒｋ６結合劑、其共軛物及使用彼之方法
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018408A1 (en) * 1994-12-13 1996-06-20 Arizona Board Of Regents Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
WO1999035164A1 (en) * 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Anti-cryptococcal peptides

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011502A (es) 1999-05-14 2003-08-20 Boehringer Ingelheim Pharma Compuestos de tipo profarmaco anti-tumorigenos, activados por enzimas.
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
EP1537140B1 (en) * 2001-11-07 2013-01-02 Agensys, Inc. Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
AU2007308792B2 (en) 2006-10-27 2013-01-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
EP2265283B1 (en) 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
EP3501546A3 (de) * 2011-04-21 2019-09-18 Seattle Genetics, Inc. Cystein-wirkstoff konjugate und ihre verwendung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018408A1 (en) * 1994-12-13 1996-06-20 Arizona Board Of Regents Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
WO1999035164A1 (en) * 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Anti-cryptococcal peptides

Also Published As

Publication number Publication date
US20130157960A1 (en) 2013-06-20
JP5791707B2 (ja) 2015-10-07
JP2013533228A (ja) 2013-08-22
WO2011154359A1 (de) 2011-12-15
CA2801971A1 (en) 2011-12-15
EP2579887A1 (de) 2013-04-17
ES2528956T3 (es) 2015-02-13
HK1184363A1 (en) 2014-01-24
CA2801971C (en) 2018-07-24
US8722629B2 (en) 2014-05-13
CN103200950A (zh) 2013-07-10
EP2579887B1 (de) 2014-11-12

Similar Documents

Publication Publication Date Title
CN103200950A (zh) 新颖的耳他汀衍生物及其用途
CN103379912B (zh) 正羧烷基耳他汀及其应用
CN103764667B (zh) N‑羧烷基耳他汀类及其应用
TWI636793B (zh) 新穎結合劑-藥物接合物（ＡＤＣｓ）及其用途（二）
EP3432934A1 (de) Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
CN104254342A (zh) 新抗体药物缀合物(adc)及其用途
CA3155093A1 (en) Selective drug release from internalized conjugates of biologically active compounds
CN118354796A (zh) 用于治疗、预防或管理过度增殖病症的化合物、药物组合物和方法
CN118556062A (zh) 用于治疗、预防或管理过度增殖病症的化合物、药物组合物和方法
HK1184363B (en) Novel auristatin derivatives and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant